The Emerging Discipline of Quantitative Systems Pharmacology
In 2011, the National Institutes of Health (NIH), in collaboration with leaders from the pharmaceutical industry and the academic community, published a white paper describing the emerging discipline of Quantitative Systems Pharmacology (QSP), and recommended the establishment of NIH-supported inter...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Online |
| Iaith: | Saesneg |
| Cyhoeddwyd: |
Frontiers Media SA
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | 19545 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
| _version_ | 1869519840971063296 |
|---|---|
| author | Tarek A. Leil Sergey Ermakov |
| author_browse | Sergey Ermakov Tarek A. Leil |
| author_facet | Tarek A. Leil Sergey Ermakov |
| author_sort | Tarek A. Leil |
| collection | Directory of Open Access Books |
| description | In 2011, the National Institutes of Health (NIH), in collaboration with leaders from the pharmaceutical industry and the academic community, published a white paper describing the emerging discipline of Quantitative Systems Pharmacology (QSP), and recommended the establishment of NIH-supported interdisciplinary research and training programs for QSP. QSP is still in its infancy, but has tremendous potential to change the way we approach biomedical research. QSP is really the integration of two disciplines that have been increasingly useful in biomedical research; “Systems Biology” and “Quantitative Pharmacology”. Systems Biology is the field of biomedical research that seeks to understand the relationships between genes and biologically active molecules to develop qualitative models of these systems; and Quantitative Pharmacology is the field of biomedical research that seeks to use computer aided modeling and simulation to increase our understanding of the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs, and to aid in the design of pre-clinical and clinical experiments. The purpose of QSP modeling is to develop quantitative computer models of biological systems and disease processes, and the effects of drug PK and PD on those systems. QSP models allow testing of numerous potential experiments “in-silico” to eliminate those associated with a low probability of success, avoiding the potential costs of evaluating all of those failed experiments in the real world. At the same time, QSP models allow us to develop our understanding of the interaction between drugs and biological systems in a more systematic and rigorous manner. As the need to be more cost-efficient in the use of research funding increases, biomedical researchers will be required to gain the maximum insight from each experiment that is conducted. This need is even more acute in the pharmaceutical industry, where there is tremendous competition to develop innovative therapies in a highly regulated environment, combined with very high research and development (R&D) costs for bringing new drugs to market (~$1.3 billion/drug). Analogous modeling & simulation approaches have been successfully integrated into other disciplines to improve the fundamental understanding of the science and to improve the efficiency of R&D (e.g., physics, engineering, economics, etc.). The biomedical research community has been slow to integrate computer aided modeling & simulation for many reasons: including the perception that biology and pharmacology are “too complex” and “too variable” to be modeled with mathematical equations; a lack of adequate graduate training programs; and the lack of support from government agencies that fund biomedical research. However, there is an active community of researchers in the pharmaceutical industry, the academic community, and government agencies that develop QSP and quantitative systems biology models and apply them both to better characterize and predict drug pharmacology and disease processes; as well as to improve efficiency and productivity in pharmaceutical R&D. |
| format | Online |
| id | doab-20.500.12854ir-46250 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-462502024-04-01T14:14:54Z The Emerging Discipline of Quantitative Systems Pharmacology Tarek A. Leil Sergey Ermakov RM1-950 Q1-390 Pharmacodynamics In-silico pharmacometrics Pharmaceutical R&D Computational Biology pharmacokinetics Quantitative Systems Pharmacology Modeling & Simulation Multi-scale modeling Systems Biology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology In 2011, the National Institutes of Health (NIH), in collaboration with leaders from the pharmaceutical industry and the academic community, published a white paper describing the emerging discipline of Quantitative Systems Pharmacology (QSP), and recommended the establishment of NIH-supported interdisciplinary research and training programs for QSP. QSP is still in its infancy, but has tremendous potential to change the way we approach biomedical research. QSP is really the integration of two disciplines that have been increasingly useful in biomedical research; “Systems Biology” and “Quantitative Pharmacology”. Systems Biology is the field of biomedical research that seeks to understand the relationships between genes and biologically active molecules to develop qualitative models of these systems; and Quantitative Pharmacology is the field of biomedical research that seeks to use computer aided modeling and simulation to increase our understanding of the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs, and to aid in the design of pre-clinical and clinical experiments. The purpose of QSP modeling is to develop quantitative computer models of biological systems and disease processes, and the effects of drug PK and PD on those systems. QSP models allow testing of numerous potential experiments “in-silico” to eliminate those associated with a low probability of success, avoiding the potential costs of evaluating all of those failed experiments in the real world. At the same time, QSP models allow us to develop our understanding of the interaction between drugs and biological systems in a more systematic and rigorous manner. As the need to be more cost-efficient in the use of research funding increases, biomedical researchers will be required to gain the maximum insight from each experiment that is conducted. This need is even more acute in the pharmaceutical industry, where there is tremendous competition to develop innovative therapies in a highly regulated environment, combined with very high research and development (R&D) costs for bringing new drugs to market (~$1.3 billion/drug). Analogous modeling & simulation approaches have been successfully integrated into other disciplines to improve the fundamental understanding of the science and to improve the efficiency of R&D (e.g., physics, engineering, economics, etc.). The biomedical research community has been slow to integrate computer aided modeling & simulation for many reasons: including the perception that biology and pharmacology are “too complex” and “too variable” to be modeled with mathematical equations; a lack of adequate graduate training programs; and the lack of support from government agencies that fund biomedical research. However, there is an active community of researchers in the pharmaceutical industry, the academic community, and government agencies that develop QSP and quantitative systems biology models and apply them both to better characterize and predict drug pharmacology and disease processes; as well as to improve efficiency and productivity in pharmaceutical R&D. 2021-02-11T12:25:50Z 2021-02-11T12:25:50Z 2016-08-16 10:34:25 2015 book 19545 16648714 9782889196425 https://directory.doabooks.org/handle/20.500.12854/46250 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/The_Emerging_Discipline_of_Quantitative_Systems_Pharmacology/681#nogo http://journal.frontiersin.org/researchtopic/2103/the-emerging-discipline-of-quantitative-systems-pharmacology Frontiers Media SA 10.3389/978-2-88919-642-5 10.3389/978-2-88919-642-5 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889196425 97 open access |
| spellingShingle | RM1-950 Q1-390 Pharmacodynamics In-silico pharmacometrics Pharmaceutical R&D Computational Biology pharmacokinetics Quantitative Systems Pharmacology Modeling & Simulation Multi-scale modeling Systems Biology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology Tarek A. Leil Sergey Ermakov The Emerging Discipline of Quantitative Systems Pharmacology |
| title | The Emerging Discipline of Quantitative Systems Pharmacology |
| title_full | The Emerging Discipline of Quantitative Systems Pharmacology |
| title_fullStr | The Emerging Discipline of Quantitative Systems Pharmacology |
| title_full_unstemmed | The Emerging Discipline of Quantitative Systems Pharmacology |
| title_short | The Emerging Discipline of Quantitative Systems Pharmacology |
| title_sort | emerging discipline of quantitative systems pharmacology |
| topic | RM1-950 Q1-390 Pharmacodynamics In-silico pharmacometrics Pharmaceutical R&D Computational Biology pharmacokinetics Quantitative Systems Pharmacology Modeling & Simulation Multi-scale modeling Systems Biology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology |
| topic_facet | RM1-950 Q1-390 Pharmacodynamics In-silico pharmacometrics Pharmaceutical R&D Computational Biology pharmacokinetics Quantitative Systems Pharmacology Modeling & Simulation Multi-scale modeling Systems Biology thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology |
| url | 19545 |
| work_keys_str_mv | AT tarekaleil theemergingdisciplineofquantitativesystemspharmacology AT sergeyermakov theemergingdisciplineofquantitativesystemspharmacology AT tarekaleil emergingdisciplineofquantitativesystemspharmacology AT sergeyermakov emergingdisciplineofquantitativesystemspharmacology |